Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness - 2NASA says Maven spacecraft that was orbiting Mars has gone silent
- 3Quandoo to shut restaurant booking platform by end of 2026
- 4Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
- 5Little Italy Mercato brings fresh food and community to downtown San Diego
- Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- Vote In favor of Your Favored Kind Of Attire
- Wedding trip Objections in the US
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Heartfelt Objections to Visit with Your Adored One
- Blue Origin launches New Glenn rocket on company's first NASA-scale science mission
- Agricultural drones are taking off globally, saving farmers time and money
- 8 Espresso Bean Starting points All over the Planet
- Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
